Versartis Closes $21M Series B
Mountain View, Calif.-based biotech company Versartis Inc., which is developing therapeutics to treat endocrine disorders, has raised $21 million in funding. New Leaf Venture Partners led the Series B round, which included participation from Advent Venture Partners' Advent Life Sciences fund and existing shareholders Index Ventures and Amunix. The money will help Versartis conduct clinical trials of its product for growth hormone deficiency.
16 February 2011•4 mins read
